Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1 [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ?A day earlier, on December 4, the company announced receiving a conditional approval for EXZOLT CATTLE-CA1 from the FDA. EXZOLT CATTLE-CA1 is a topical solution containing fluralaner. The drug prevents and treats infestations caused by the New World screwworm larvae, which cause myiasis. Management noted that the regulatory process was accelerated by the FDA through priority zoonotic drug designation for treatments addressing serious diseases, speeding EXZOLT's availability. The drug is still pending a full demonstration of effectiveness and is only conditionally approved. Management noted that CATTLE-CA1 will be available for prescription in the first quarter of 2025. ?Analysts from Guggenheim noted that their increased price target of Merck & Co., Inc. (NYSE:MRK) is based on the inclusion of probability-adjusted revenues for Winrevair in patients with Combined Post and Precapillary Pulmo
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.MarketBeat
- Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIRâ„¢ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)Business Wire
- Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104 [Yahoo! Finance]Yahoo! Finance
- Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website